Page last updated: 2024-10-28
miltefosine and Blood Diseases
miltefosine has been researched along with Blood Diseases in 1 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Research Excerpts
Excerpt | Relevance | Reference |
"Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 6.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
"Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 2.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
Sindermann, H | 1 |
Engel, J | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status |
Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed |
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
1 review available for miltefosine and Blood Diseases